Value of accelerated multimodality therapy in stage IIIA and IIIB non–small cell lung cancer Malcolm M DeCamp, MD, Thomas W Rice, MD, David J Adelstein,

Slides:

Advertisements

Similar presentations

Thomas W. Rice, MD, Deepak Khuntia, MD, Lisa A. Rybicki, MS, David J

Advertisements

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

Characterization and Importance of Air Leak After Lobectomy

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Relationship between margin distance and local recurrence among patients undergoing wedge resection for small (≤2 cm) non–small cell lung cancer Kamran.

Should lung transplantation be performed for patients on mechanical respiratory support? The US experience David P. Mason, MD, Lucy Thuita, MS, Edward.

Siva Raja, MD, PhD, Thomas W. Rice, MD, John Ehrlinger, PhD, John R

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Effect of changes in postoperative spirometry on survival after lung transplantation David P. Mason, MD, Jeevanantham Rajeswaran, MSc, Liang Li, PhD,

Endovascular versus open elephant trunk completion for extensive aortic disease Eric E. Roselli, MD, Sreekumar Subramanian, MD, Zhiyuan Sun, BS, Jahanzaib.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Surgical treatment of pseudoaneurysm of the thoracic aorta

Surgical Treatment of Postinfarction Left Ventricular Pseudoaneurysm

Esophageal submucosa: The watershed for esophageal cancer

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Survival after resection of synchronous non–small cell lung cancer

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Duration of inotropic support after left ventricular assist device implantation: Risk factors and impact on outcome Soren Schenk, MD, Patrick M. McCarthy,

Reoperation After Mitral Valve Repair for Degenerative Disease

Bruce W. Lytle, MD, Eugene H. Blackstone, MD, Joseph F

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy.

Sina Ercan, MD, Thomas W. Rice, MD, Sudish C. Murthy, MD, PhD, Lisa A

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Clostridium difficile infection after cardiac surgery: Prevalence, morbidity, mortality, and resource utilization Suresh Keshavamurthy, MBBS, MS, Colleen.

Kwhanmien Kim, MD, Thomas W. Rice, MD, Sudish C

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Prosthesis size and long-term survival after aortic valve replacement

Too High for Transplantation

Should lung transplantation be performed using donation after cardiac death? The United States experience David P. Mason, MD, Lucy Thuita, MS, Joan M.

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Does a similar procedure result in similar survival for women and men undergoing isolated coronary artery bypass grafting? Tamer Attia, MD, MSc, Colleen.

Aortic valve replacement: Is valve size important?

Refining esophageal cancer staging

Atrial fibrillation complicating lung cancer resection

Stage III non–small cell lung cancer and metachronous brain metastases

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Reduced survival in women after valve surgery for aortic regurgitationEffect of aortic enlargement and late aortic rupture Monica L. McDonald, MDa, Nicholas.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Superficial adenocarcinoma of the esophagus

Reintervention After Heller Myotomy for Achalasia: Is It Inevitable?

Distal aortic interventions after repair of ascending dissection: The argument for a more aggressive approach Eric E. Roselli, MD, Gabriel Loor, MD,

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Sudish C. Murthy, MD, PhD, Edward R. Nowicki, MD, MS, David P

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration.

David P. Mason, MD, Dale H. Marsh, MD, Joan M. Alster, MS, Sudish C

Long-term effectiveness of operations for ascending aortic dissections

Decision support in surgical management of ischemic cardiomyopathy

Impact of Anastomotic Airway Complications After Lung Transplantation

Intermediate survival in neonates with aortic atresia: A multi-institutional study Marshall L. Jacobs, MD, Eugene H. Blackstone, MD, Leonard L. Bailey,

M1a/M1b esophageal carcinoma: Clinical relevance

Thomas W. Rice, MD, Deepak Khuntia, MD, Lisa A. Rybicki, MS, David J

Patient and Surgical Factors Influencing Air Leak After Lung Volume Reduction Surgery: Lessons Learned From the National Emphysema Treatment Trial Malcolm.

Mohammed A Quader, MD, Patrick M McCarthy, MD, A

Is repair preferable to replacement for ischemic mitral regurgitation?

N1 esophageal carcinoma: The importance of staging and downstaging

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Superior sulcus lung tumors: Impact of local control on survival

Mitral valve repair with aortic valve replacement is superior to double valve replacement A.Marc Gillinov, MD, Eugene H Blackstone, MD, Delos M Cosgrove,

Siva Raja, MD, PhD, Jay J. Idrees, MD, Eugene H

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Lung Transplantation for Idiopathic Pulmonary Fibrosis

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Presentation transcript:

Value of accelerated multimodality therapy in stage IIIA and IIIB non–small cell lung cancer Malcolm M DeCamp, MD, Thomas W Rice, MD, David J Adelstein, MD, Mark A Chidel, MD, Lisa A Rybicki, MS, Sudish C Murthy, MD, PhD, Eugene H Blackstone, MD The Journal of Thoracic and Cardiovascular Surgery Volume 126, Issue 1, Pages 17-25 (July 2003) DOI: 10.1016/S0022-5223(03)00206-X

Figure 1 Treatment schema for accelerated hyperfractionated chemoradiotherapy followed by resection and adjuvant, consolidative chemoradiation for patients with stage IIIA and stage IIIB NSCLC. Cisplatin dose was 20 mg · m−2 · d−1 for 4 days and paclitaxel dose was 175 mg · m−2 as 24-hour infusion. CDDP, Cisplatin; BID RT, twice-daily radiotherapy at 1.5 Gy per fraction. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 17-25DOI: (10.1016/S0022-5223(03)00206-X)

Figure 2 Postoperative survival after accelerated chemoradiotherapy. A, Survival. Each circle represents death positioned on vertical axis according to Kaplan-Meier estimator. These are accompanied by vertical bars representing asymmetric 68% confidence limits (equivalent to ±1 SE). Numbers in parentheses represent survivors at that interval. Smooth curve is parametric estimate of survival enclosed within dashed asymmetric 68% confidence bands. B, Hazard. Instantaneous risk of death (hazard function) is represented by solid curve enclosed within dashed 68% confidence limits. Although early risk is high, this hazard is of short duration, resulting in few early deaths. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 17-25DOI: (10.1016/S0022-5223(03)00206-X)

Figure 3 Survival by pathologic stage. Both Kaplan-Meier (symbols) and parametric (curves) survival estimates are depicted as in Figure 2, A. Parametric estimates are truncated when remaining survivors are few. Patients with pathologic stage 0 to II had survival superior to those with residual N2 disease (stage IIIA), who in turn had longer survival than did nonresponders (stage IIIB, P < .001). The Journal of Thoracic and Cardiovascular Surgery 2003 126, 17-25DOI: (10.1016/S0022-5223(03)00206-X)

Figure 4 Good risk and poor risk patients. Shown at upper portion of graph is 45-year-old patient whose adenocarcinoma was sterilized by accelerated chemoradiotherapy. For comparison, we present same patient profile except with squamous cell carcinoma. Survival at bottom of graph is for 65-year-old patient who did not respond to therapy and was found to have T4 tumor at surgery. Two curves represent squamous and nonsquamous tumor histologic types. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 17-25DOI: (10.1016/S0022-5223(03)00206-X)